Verified factor-similar pair

ISCV vs MDYV

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB HML
Similarity score
89
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • MDYV has the higher backtested relative Sharpe (0.894 vs 0.861).
  • ISCV has the lower published fee (0.06% vs 0.15%).
  • MDYV is cheaper on dividend valuation (116 vs 124, where 100 is each fund's historical median).
  • ISCV has the stronger regression fit (adjusted R-squared 0.970 vs 0.949).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

ISCV

iShares Morningstar Small Cap Value ETF
SMB HML
Adj. R2
0.970
Rel. Sharpe
0.861
Mkt beta
1.01
AUM
US$631M
MER
0.06%
Valuation
124

MDYV

State Street SPDR S&P 400 Mid Cap Value ETF
SMB HML
Adj. R2
0.949
Rel. Sharpe
0.894
Mkt beta
0.98
AUM
US$2.5B
MER
0.15%
Valuation
116

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
ISCV
+0.70
|t|
+24.2
MDYV
+0.50
|t|
+14.2
diff +0.20
HML
ISCV
+0.38
|t|
+13.6
MDYV
+0.29
|t|
+8.5
diff +0.09
RMW
ISCV
+0.12
|t|
+3.3
MDYV
+0.17
|t|
+4.1
diff -0.05
CMA
ISCV
+0.07
|t|
+1.7
MDYV
+0.03
|t|
+0.6
diff +0.04
UMD
ISCV
-0.12
|t|
-7.0
MDYV
-0.07
|t|
-3.6
diff -0.04

Why This Pair Matches

Exposure level
87
Exposure shape
99
Mkt beta diff
0.03
Rel. Sharpe diff
0.033

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

ISCV fund page MDYV fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.